FDA approves new indication for Eisai’s Fycompa

WOODCLIFF LAKE, N.J. — Eisai announced Monday that the Food and Drug Administration had given the company approval for a new indication for its seizure treatment Fycompa. The medication has been approved as an adjunctive therapy in treating primary generalized tonic-clonic seizures (PGTC). 

The approval of FYCOMPA to treat patients age 12 and older with PGTC seizures represents an important next step toward expanding treatment options for patients whose PGTC seizures are not adequately controlled with their current medication,” Lynn Kramer Eisai’s chief clinical officer and president of Eisai’s Neuroscience and General Marketing Unit, said. “Eisai is committed to advancing epilepsy care and making contributions to help address the diversified needs of epilepsy patients and their families as part of its corporate humane healthcare mission.”

Fycompa is available in 2-, 4-, 6-, 8-, 10- and 12-mg dosage strengths, and patients who are eligible can register at Fycompa.com for a Fycompa savings card.